Literature DB >> 27990323

Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement.

Pauline Gravelle1, Catherine Do2, Camille Franchet3, Sabina Mueller4, Lucie Oberic5, Loïc Ysebaert6, Luigi Maria Larocca7, Stefan Hohaus8, Marie-Noëlle Calmels9, François-Xavier Frenois10, Robert Kridel11, Randy D Gascoyne11, Guy Laurent6, Pierre Brousset12, Salvatore Valitutti13, Camille Laurent14.   

Abstract

Upregulation of T cell immunoglobulin-3 (TIM-3) has been associated with negative regulation of the immune response in chronic infection and cancer, including lymphoma. Here, we investigated the possible correlation between TIM-3 expression by ex vivo cytotoxic T cells (CTL) from follicular lymphoma (FL) biopsies and their functional unresponsiveness that could limit the favorable impact of CTL on disease progression. We report a high percentage of CD8+TIM-3+T cells in lymph nodes of FL patients. When compared to their CD8+TIM-3- counterparts, CD8+TIM-3+ T cells exhibited defective cytokine production following TCR engagement. Furthermore, CD8+TIM-3+ T cells display ex vivo markers of lytic granule release and remain unresponsive to further TCR-induced activation of the lytic machinery. Although confocal microscopy showed that TIM-3 expression on CD8+ T cells correlated with minor alterations of immunological synapse, a selective reduction of ERK signaling in CD8+TIM-3+T cells was observed by phospho-flow analysis. Finally, short relapse-free survival despite rituximab(R)-chemotherapy was observed in patients with high content of TIM-3+ cells and a poor infiltrate of granzyme B+ T cells in FL lymph nodes. Together, our data indicate that, besides selective TCR early signaling defects, TIM-3 expression correlates with unresponsiveness of ex vivo CD8+ T cells in FL. They show that scores based on the combination of exhaustion and cytolytic markers in FL microenvironment might be instrumental to identify patients at early risk of relapses following R-chemotherapy.

Entities:  

Keywords:  CD8+ T cell dysfunction; T cell exhaustion; TCR signaling impairment; TIM-3 immune-checkpoint; follicular lymphoma; immunological synapse; prognostic value

Year:  2016        PMID: 27990323      PMCID: PMC5135226          DOI: 10.1080/2162402X.2016.1224044

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  44 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Whole-slide imaging is a robust alternative to traditional fluorescent microscopy for fluorescence in situ hybridization imaging using break-apart DNA probes.

Authors:  Camille Laurent; Maxime Guérin; François-Xavier Frenois; Valérie Thuries; Laurence Jalabert; Pierre Brousset; Séverine Valmary-Degano
Journal:  Hum Pathol       Date:  2013-03-18       Impact factor: 3.466

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors:  Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

5.  Regulation of asymmetric division and CD8+ T lymphocyte fate specification by protein kinase Cζ and protein kinase Cλ/ι.

Authors:  Patrick J Metz; Janilyn Arsenio; Boyko Kakaradov; Stephanie H Kim; Kelly A Remedios; Katherine Oakley; Kazunori Akimoto; Shigeo Ohno; Gene W Yeo; John T Chang
Journal:  J Immunol       Date:  2015-01-23       Impact factor: 5.422

Review 6.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

7.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

Authors:  Alan G Ramsay; Andrew J Clear; Gavin Kelly; Rewas Fatah; Janet Matthews; Finlay Macdougall; T Andrew Lister; Abigail M Lee; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

Review 8.  The costimulatory role of TIM molecules.

Authors:  Roselynn Rodriguez-Manzanet; Rosemarie DeKruyff; Vijay K Kuchroo; Dale T Umetsu
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Several immune escape patterns in non-Hodgkin's lymphomas.

Authors:  Camille Laurent; Konstantina Charmpi; Pauline Gravelle; Marie Tosolini; Camille Franchet; Loïc Ysebaert; Pierre Brousset; Alexandre Bidaut; Bernard Ycart; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

View more
  12 in total

Review 1.  Role of the microenvironment across histological subtypes of NHL.

Authors:  Karin Tarte
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  EBV infection determines the immune hallmarks of plasmablastic lymphoma.

Authors:  Pauline Gravelle; Sarah Péricart; Marie Tosolini; Bettina Fabiani; Paul Coppo; Nadia Amara; Alexandra Traverse-Gléhen; Nathalie Van Acker; Pierre Brousset; Jean-Jacques Fournie; Camille Laurent
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

3.  Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.

Authors:  Philippe Armand; Ann Janssens; Giuseppe Gritti; John Radford; John Timmerman; Antonio Pinto; Santiago Mercadal Vilchez; Peter Johnson; David Cunningham; John P Leonard; Scott J Rodig; Patricia Martín-Regueira; Anne Sumbul; Selda Samakoglu; Hao Tang; Stephen M Ansell
Journal:  Blood       Date:  2021-02-04       Impact factor: 22.113

4.  Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8+ T-cells despite immune checkpoint signaling.

Authors:  Adam M Greenbaum; Jonathan R Fromm; Ajay K Gopal; A McGarry Houghton
Journal:  Blood Res       Date:  2022-05-13

Review 5.  Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Authors:  Pauline Gravelle; Barbara Burroni; Sarah Péricart; Cédric Rossi; Christine Bezombes; Marie Tosolini; Diane Damotte; Pierre Brousset; Jean-Jacques Fournié; Camille Laurent
Journal:  Oncotarget       Date:  2017-07-04

Review 6.  Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma.

Authors:  Mojgan Djavaheri-Mergny; Sylvie Giuriato; Mario P Tschan; Magali Humbert
Journal:  Cells       Date:  2019-01-30       Impact factor: 6.600

7.  Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Authors:  Hsiling Chiu; Preeti Trisal; Chad Bjorklund; Soraya Carrancio; Estela G Toraño; Carla Guarinos; Despoina Papazoglou; Patrick R Hagner; Asma Beldi-Ferchiou; Karin Tarte; Marie-Hélène Delfau-Larue; Franck Morschhauser; Alan G Ramsay; Anita K Gandhi
Journal:  Br J Haematol       Date:  2019-02-14       Impact factor: 6.998

8.  Integrative network modeling reveals mechanisms underlying T cell exhaustion.

Authors:  Hamid Bolouri; Mary Young; Joshua Beilke; Rebecca Johnson; Brian Fox; Lu Huang; Cristina Costa Santini; Christopher Mark Hill; Anne-Renee van der Vuurst de Vries; Paul T Shannon; Andrew Dervan; Pallavur Sivakumar; Matthew Trotter; Douglas Bassett; Alexander Ratushny
Journal:  Sci Rep       Date:  2020-02-05       Impact factor: 4.379

Review 9.  PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.

Authors:  Zijun Y Xu-Monette; Jianfeng Zhou; Ken H Young
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476

10.  Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.

Authors:  Sarah Péricart; Marie Tosolini; Pauline Gravelle; Cédric Rossi; Alexandra Traverse-Glehen; Nadia Amara; Camille Franchet; Elodie Martin; Christine Bezombes; Guy Laurent; Pierre Brousset; Jean-Jacques Fournié; Camille Laurent
Journal:  Cancers (Basel)       Date:  2018-10-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.